Back to search results

Understanding Transformed Splenic Marginal Zone Lymphoma

This study is looking at Transformed Splenic Marginal Zone Lymphoma (t-SMZL), a rare type of cancer that is difficult to treat. Researchers want to better understand the genetic changes (mutations, copy number abnormalities, and structural variants) that happen in t-SMZL. They will look at these changes both when the original Splenic Marginal Zone Lymphoma (SMZL) is diagnosed and when it transforms into t-SMZL. The goal is to find out what causes this transformation and to identify new ways to treat it. You might be able to join if you are an adult (18 or older) with a diagnosis of t-SMZL and have available tumor tissue samples. This is an observational study, meaning researchers will collect and analyze existing information, not test new treatments.

Study design
This is an observational study planning to include 100 participants. Researchers will collect and analyze existing medical information and tumor samples.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will analyze data up to 30 months from the end of sample collection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06712459

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

Recruiting
Not specifiedAges 18+Observational
International Extranodal Lymphoma Study Group (IELSG)
~100 participants
Updated 2026-01-16 on ClinicalTrials.gov

At a glance

Recruiting sites
3 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Prevalence of mutations, copy number abnormalities and structural variants at SMZL diagnosis and at HT
Measured over 30 months: from the end of samples collection to the end of study analysis
+2 more outcomes measured

Conditions

Transformed Splenic Marginal Zone Lymphoma

Explore related trials

Splenic Marginal Zone Lymphoma

Where it's being run

7 sites across 7 states
New York1
Belgium1
France1
Italy1
Spain1
Switzerland1
United Kingdom1

Study leadership

  • Luca Arcaini, MD · STUDY_CHAIR · Fondazione IRCCS Policlinico San Matteo
  • Davide Rossi, MD · STUDY_CHAIR · Oncology Institute of Southern Switzerland (IOSI) and Institute of Oncology Research (IOR)

Who to contact

IELSG Study Coordination Office
[email protected]
+41 58 666 7321
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

None

What this trial measures

  • Prevalence of mutations, copy number abnormalities and structural variants at SMZL diagnosis and at HT30 months: from the end of samples collection to the end of study analysis
  • Quantification and qualification of lesions acquired at the time of HT.30 months: from the end of samples collection to the end of study analysis
  • Prevalence of clonal relationship between SMZL and HT30 months: from the end of samples collection to the end of study analysis